Artikel ; Online: Update on gepants for the treatment of chronic migraine.
Journal of the Chinese Medical Association : JCMA
2024 Band 87, Heft 4, Seite(n) 350–356
Abstract: Chronic migraine (CM) is a profoundly debilitating condition that has detrimental clinical and social outcomes. Over the past two decades, novel small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists, known as gepants, and CGRP ... ...
| Abstract | Chronic migraine (CM) is a profoundly debilitating condition that has detrimental clinical and social outcomes. Over the past two decades, novel small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists, known as gepants, and CGRP monoclonal antibodies (mAbs) have been developed, ushering in a new era of migraine-specific treatment. In this review, we discuss the literature investigating the role of gepants for the treatment of CM. Numerous completed and ongoing clinical studies have conclusively demonstrated the safety, tolerability, and efficacy of several gepants for the acute treatment of migraine. However, preventive trials involving gepants have focused on patients with episodic migraine, with atogepant being the only gepant approved for CM prevention by the US Food and Drug Administration at the time of writing. Although some preliminary positive results have been reported, further research is still required to achieve additional advancements in the future. In summary, the effectiveness of gepants for treating individuals with CM are highly expected. This review highlights the development and current progress of gepants for the treatment of CM, focusing both on their role as acute abortive agents and preventive measures and on their concomitant use with other antimigraine medications, such as CGRP mAbs or triptans. |
|||||
|---|---|---|---|---|---|---|
| Mesh-Begriff(e) | Humans ; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use ; Calcitonin Gene-Related Peptide ; Migraine Disorders/drug therapy ; Antibodies, Monoclonal/therapeutic use ; Tryptamines/therapeutic use | |||||
| Chemische Substanzen | Calcitonin Gene-Related Peptide Receptor Antagonists ; Calcitonin Gene-Related Peptide (JHB2QIZ69Z) ; Antibodies, Monoclonal ; Tryptamines | |||||
| Sprache | Englisch | |||||
| Erscheinungsdatum | 2024-02-13 | |||||
| Erscheinungsland | Netherlands | |||||
| Dokumenttyp | Review ; Journal Article | |||||
| ZDB-ID | 2107283-8 | |||||
| ISSN | 1728-7731 ; 1726-4901 | |||||
| ISSN (online) | 1728-7731 | |||||
| ISSN | 1726-4901 | |||||
| DOI | 10.1097/JCMA.0000000000001070 | |||||
| Signatur |
|
|||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 2699: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.